Heron Therapeutics, Inc. (HRTX)
0.3028
+0.01
(+2.23%)
USD |
NASDAQ |
Oct 23, 16:00
0.3003
0.00 (0.00%)
After-Hours: 20:00
Heron Therapeutics Enterprise Value : 164.11M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 164.11M |
| October 22, 2026 | 162.86M |
| October 21, 2026 | 170.93M |
| October 20, 2026 | 173.90M |
| October 19, 2026 | 175.12M |
| October 16, 2026 | 175.13M |
| October 15, 2026 | 178.07M |
| October 14, 2026 | 175.32M |
| October 13, 2026 | 180.74M |
| October 12, 2026 | 185.48M |
| October 09, 2026 | 183.68M |
| October 08, 2026 | 174.60M |
| October 07, 2026 | 179.55M |
| October 06, 2026 | 169.58M |
| October 05, 2026 | 176.84M |
| October 02, 2026 | 172.60M |
| October 01, 2026 | 174.17M |
| September 30, 2026 | 166.14M |
| September 29, 2026 | 164.71M |
| September 28, 2026 | 162.02M |
| September 25, 2026 | 162.48M |
| September 24, 2026 | 161.68M |
| September 23, 2026 | 161.87M |
| September 22, 2026 | 163.39M |
| September 21, 2026 | 157.89M |
| Date | Value |
|---|---|
| September 18, 2026 | 165.42M |
| September 17, 2026 | 166.55M |
| September 16, 2026 | 166.95M |
| September 15, 2026 | 166.23M |
| September 14, 2026 | 166.48M |
| September 11, 2026 | 166.51M |
| September 10, 2026 | 167.80M |
| September 09, 2026 | 169.83M |
| September 08, 2026 | 173.05M |
| September 04, 2026 | 171.90M |
| September 03, 2026 | 169.26M |
| September 02, 2026 | 166.02M |
| September 01, 2026 | 166.42M |
| August 31, 2026 | 166.99M |
| August 28, 2026 | 168.62M |
| August 27, 2026 | 169.66M |
| August 26, 2026 | 165.89M |
| August 25, 2026 | 167.95M |
| August 24, 2026 | 167.90M |
| August 21, 2026 | 167.03M |
| August 20, 2026 | 165.28M |
| August 19, 2026 | 166.40M |
| August 18, 2026 | 163.75M |
| August 17, 2026 | 167.37M |
| August 14, 2026 | 170.53M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tonix Pharmaceuticals Holding Corp. | -88.14M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.489M |
| Revenue (Quarterly) | 37.67M |
| Total Expenses (Quarterly) | 43.16M |
| EPS Diluted (Quarterly) | -0.0288 |
| Gross Profit Margin (Quarterly) | 69.28% |
| Profit Margin (Quarterly) | -14.57% |
| Earnings Yield | -62.75% |
| Normalized Earnings Yield | -46.96 |